Halozyme Therapeutics (NASDAQ: HALO) — Company Overview, News & Financial Data
Halozyme Therapeutics is a biotechnology firm focused on innovative oncology therapies and its proprietary ENHANZE® drug delivery technology.
Halozyme Therapeutics
Halozyme Therapeutics is a biopharmaceutical company focused on developing and commercializing novel drug delivery technologies and specialty biopharmaceuticals. The company's primary proprietary platform, ENHANZE, utilizes a recombinant human hyaluronidase enzyme (rHuPH20) to temporarily degrade hyaluronan in the extracellular matrix, facilitating the rapid subcutaneous administration of biopharmaceutical products typically delivered intravenously. Halozyme licenses ENHANZE to major global pharmaceutical partners to co-formulate with commercial therapeutics across oncology, immunology, and rare disease therapeutic areas. Additionally, the company manufactures and markets advanced auto-injector and specialty drug delivery devices for subcutaneous self-administration of biologic drugs and small molecule therapeutics.
Snapshot
Operations
Products and/or services of Halozyme Therapeutics
- Drug Delivery Technology: Proprietary drug delivery platform utilizing recombinant human hyaluronidase enzyme to facilitate rapid subcutaneous delivery of co-formulated biopharmaceutical therapeutics, reducing patient infusion times and healthcare administration costs across multiple therapeutic areas globally.
- Oncology Partnered Products: Commercial licensing partnerships with global biopharmaceutical companies that integrate subcutaneous drug delivery enzyme technology into approved oncology biologics, generating recurring royalty revenues and milestone payments from large-volume injectable cancer treatments worldwide.
- Auto-Injector Delivery Systems: Engineering, development, and commercial supply of advanced high-volume auto-injectors and specialty drug-device combination products designed for patient self-administration of biopharmaceutical injectables and small-molecule medications across oncology and rare disease indications.
- Non-Oncology Biologic Formulations: Subcutaneous drug delivery licensing agreements covering non-oncology biopharmaceutical indications, enabling rapid injection of therapies for autoimmune, neurological, and rare diseases, including subcutaneous immunoglobulins and targeted monoclonal antibody therapies for international partner biopharmaceutical firms.
- Active Pharmaceutical Ingredient Supply: Bulk commercial manufacturing and supply of proprietary recombinant human hyaluronidase enzyme under strict quality control standards, delivering active pharmaceutical ingredients directly to drug manufacturing partners for co-formulation and finished drug product packaging.
- Biopharmaceutical Research and Development: Applied laboratory research and clinical formulation studies focused on expanding subcutaneous delivery capabilities, optimizing biologic formulation stability, evaluating potential therapeutic targets, and advancing next-generation drug delivery technologies for injectable specialty biopharmaceuticals.
Halozyme Therapeutics executive team
- Dr. Helen I. Torley M.B. Ch. B., M.R.C.P.President, CEO & Director
- Ms. Nicole LaBrosse CPASenior VP & CFO
- Mr. Mark Snyder Esq.Senior VP, General Counsel, Chief Compliance Officer & nd Secretary
- Ms. Cortney Caudill M.B.A.Senior VP & COO
- Ms. Tram BuiHead of Investor Relations & Corporate Communications
- Dr. Christopher Wahl M.B.A., M.D.Chief Scientific Officer
- Dr. Charles P. Theuer M.D., Ph.D.Chief Medical Officer
- Mr. Paul SpenceChief Commercial Officer
- Mr. Rhys de CallierChief Strategy Officer
- Mr. Chase Coffman Ph.D.President of Hypercon